We are experiencing an antimicrobial resistance (AMR) crisis, brought on by the drying up of
the antibiotic discovery pipeline and the resulting unchecked spread of resistant pathogens …

ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter …

Covering: 2006 to 2017 Actinomycetes have been, for decades, one of the most important
sources for the discovery of new antibiotics with an important number of drugs and analogs …

The rising prevalence of multidrug-resistant bacteria is an urgent health crisis that can only
be countered through renewed investment in the discovery and development of antibiotics …

Drug-resistant bacteria pose a serious threat to human health worldwide. Current antibiotics
are losing efficacy and new antimicrobial agents are urgently needed. Living organisms are …

The declining trends in microbial metabolite and natural products research and the
refocusing of this research area are discussed. Renewing natural products research …

There is a continuous need for iterative cycles of antibiotic discovery and development to
deal with the selection of resistant pathogens that emerge as therapeutic application of an …

An ideal antibiotic is an antibacterial agent that kills or inhibits the growth of all harmful
bacteria in a host, regardless of site of infection without affecting beneficial gut microbes (gut …

The growing resistance of microorganisms towards antibiotics has become a serious global
problem. Therapeutics with novel chemical scaffolds and/or mechanisms of action are …

Covering: up to the end of May 2012 Riboflavin-based coenzymes, tightly bound to enzymes
catalyzing substrate oxidations and reductions, enable an enormous range of chemical …